The Albert B. Sabin Vaccine Institute, Inc.
Nonprofit global health organization focused on advancing vaccine research and development, expanding immunization programs, and supporting vaccine access, acceptance, and delivery worldwide. Activities documented include candidate vaccine development and clinical trials, applied epidemiology and vaccine effectiveness studies, CMC program management, regulatory engagement with major agencies, data dashboards for immunization insights, and delivery of investigational vaccines during outbreaks.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
US-9526777-B2
View Details
Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
US-9526777-B2
View DetailsProducts
Global Immunization Insights Dashboard
Web-based dashboard aggregating factors that affect immunization to support planning and efforts to increase vaccine reach.
Global Immunization Insights Dashboard
Web-based dashboard aggregating factors that affect immunization to support planning and efforts to increase vaccine reach.
Services
End-to-end support for advancing vaccine candidates from preclinical work through early-phase clinical development, including translational immunology and preclinical models.
Clinical trial design, site coordination, monitoring, and quality assurance for Phase 1–2 vaccine studies, including rapid deployment during outbreaks.
Field epidemiology, vaccine effectiveness studies, and program evaluations to inform immunization policy and implementation.
Development of dashboards and analytics that aggregate immunization-related indicators to inform program planning and track progress.
Building multisector partnerships and securing public and philanthropic funding to support vaccine R&D and immunization initiatives.
End-to-end support for advancing vaccine candidates from preclinical work through early-phase clinical development, including translational immunology and preclinical models.
Clinical trial design, site coordination, monitoring, and quality assurance for Phase 1–2 vaccine studies, including rapid deployment during outbreaks.
Field epidemiology, vaccine effectiveness studies, and program evaluations to inform immunization policy and implementation.
Development of dashboards and analytics that aggregate immunization-related indicators to inform program planning and track progress.
Building multisector partnerships and securing public and philanthropic funding to support vaccine R&D and immunization initiatives.
Expertise Areas
- Vaccine development and translational immunology
- Clinical trial management and clinical operations
- Chemistry, Manufacturing and Controls (CMC) program leadership
- Regulatory strategy and submissions (FDA/EMA and novel pathways)
Key Technologies
- Recombinant protein vaccine platforms
- Adenoviral vector vaccine platforms
- Subunit and microbial vaccine platforms
- Animal models for filovirus and infectious disease research
News & Updates
Explains the timeline, Sabin’s role in delivering investigational vaccines during the Rwanda outbreak, the clinical trial, and lessons for future collaborations.
Announcement and description of a dashboard intended to provide a broader view of factors impacting immunization.
Call for nominations for awards recognizing contributions to vaccinology and early- to mid-career professionals.
Explains the timeline, Sabin’s role in delivering investigational vaccines during the Rwanda outbreak, the clinical trial, and lessons for future collaborations.
Announcement and description of a dashboard intended to provide a broader view of factors impacting immunization.
Call for nominations for awards recognizing contributions to vaccinology and early- to mid-career professionals.